Prevention of Persistent Opioid Use in Mothers
- Conditions
- Opioid UsePostpartum DisorderChronic Pain Syndrome
- Interventions
- Drug: Placebo
- Registration Number
- NCT03472521
- Lead Sponsor
- Stanford University
- Brief Summary
Our previous work has identified the group of women at risk for prolonged pain, opioid use and poor functional recovery after childbirth. The optimal intervention to mitigate this risk is unknown. We propose to test an analgesic adjutant that is commonly used for post-operative pain compared to placebo to improve post-partum recovery.
- Detailed Description
A small percent of the large population of women who give birth have difficulty with prolonged pain, opioid use and poor functional recovery. This may be the first opiate exposure and significant health challenge in a young woman's life.
In our previous work, we have identified 20% who are at highest risk for prolonged pain and delayed opioid cessation and functional recovery with usual care. Moderate to severe pain on postpartum day 1 is a significant predictor of being in the risk group. The optimal intervention to mitigate this risk is unknown.
We plan to test an intervention of low dose gabapentin or placebo to be escalated by a pain medicine doctor as needed. We hypothesize that additional care of women predicted to be higher need by virtue of their postoperative day one pain score (\> 6 x2) despite usual multimodal analgesic care will lead to reduced need for opioid, less pain and more rapid functional recovery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 78
- Delivery within 5 days, able to provide informed consent, English speaker
- Opiate use disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Placebo Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist. Gabapentin Gabapentin Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
- Primary Outcome Measures
Name Time Method Time to Opioid Cessation as a Measure of Opioid Utilization Up to 12 weeks
- Secondary Outcome Measures
Name Time Method Pain Report 12 weeks Number of weeks after delivery until resolution of pain as reported by participants. Pain score was averaged each week from daily reporting by participants using a numerical rating scale (range: 1-10, 1 = no pain; 10 = worst pain).
Functional Recovery 12 weeks Functional recovery was assessed as the number of weeks after delivery until participants reported they were able to return to pre-delivery function.
Trial Locations
- Locations (1)
Lucille Packard Children's Hospital
🇺🇸Palo Alto, California, United States